FDA grants IND for dry eye product

Article

Novagali Pharma's Investigational New Drug Application (IND) to conduct a pivotal Phase III clinical trial of its dry eye candidate, Nova22007, has been granted by the FDA.

Novagali Pharma's Investigational New Drug Application (IND) to conduct a pivotal Phase III clinical trial of its dry eye candidate, Nova22007, has been granted by the FDA.

Nova22007 is a cyclosporine A ophthalmic product developed for the treatment of patients with moderate to severe dry eye syndrome. The proprietary cationic emulsion enables penetration of the drug into tissues of the ocular surface.

The planned double-masked, randomized, vehicle-controlled study will evaluate the efficacy of Nova22007 in relieving objective and subjective dry eye symptoms.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.